Neurocrine Biosciences company profile

NBIX · NASDAQ · USD

Compare Neurocrine Biosciences
$165.92Change from previous close: +0.37%Absolute change: +$0.61

Close · November 17, 2026

Company profile

Neurocrine Biosciences has 2,500 employees and is headquartered in San Diego, United States.

Neurocrine Biosciences sells its medicines mainly to patients with neurological and psychiatric disorders, and to patients with endocrine and immunological conditions, in the United States and in other markets outside the country. Its marketed products include INGREZZA, for tardive dyskinesia and chorea linked to Huntington's disease, Orilissa and Oriahnn for gynecological conditions, and CRENESSITY for congenital adrenal hyperplasia, alongside ALKINDI and Efmody. Its pipeline in clinical development targets movement disorders, major depressive disorder, schizophrenia, Alzheimer's disease, epilepsy and obesity. The company also works under license and collaboration agreements with partners including Takeda, Sanofi, AbbVie and Xenon Pharmaceuticals.

In the fiscal year ended December 2025, Neurocrine Biosciences reported revenue of 2.9 billion US dollars, up 21.4% from the previous year, and net income of 478.6 million US dollars. The company was founded in 1992 and is headquartered in San Diego, California, with 2,500 employees.

Company facts

Industry
Drug Manufacturers - Specialty & Generic
Headquarters
6027 Edgewood Bend Court, 92130, San Diego
Employees
2,500
Chief executive
Kyle Gano
Founded
1992
Fiscal year
January - December
Listing
NBIX · NASDAQ
Currency
USD
ISIN
US64125C1099

Neurocrine Biosciences and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Neurocrine BiosciencesNBIXUnited States$16.73B2,50026.6%24.5
ViatrisVTRSUnited States$23.58B30,000——
United TherapeuticsUTHRUnited States$25.04B1,40039.4%22.2
ZoetisZTSUnited States$33.92B14,50037.9%14.1
Teva Pharmaceutical IndustriesTEVAUnited States$49.67B31,17319.8%99.0
Hims & Hers HealthHIMSUnited States$4.13B2,442-6.4%—

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Neurocrine Biosciences with its competitors